mbiomics Appoints Seasoned Microbiome Expert Christopher Weidenmaier as Chief Scientific Officer

24 Oct 2023
www.biospace.com
Executive ChangeMicrobial therapy
MUNICH--(BUSINESS WIRE)-- mbiomics today announced the appointment of Christopher Weidenmaier, PhD, as Chief Scientific Officer (CSO). Dr. Weidenmaier will contribute nearly 20 years of experience in the microbiome and infectious diseases fields and lead the company’s discovery and development efforts as they establish a pipeline of complex microbiome ecosystems product candidates. Over the course of his career, Dr. Weidenmaier has successfully developed and led R&D efforts for next-generation microbiome products. The appointment will strategically expand the mbiomics’ leadership team on its mission to harness the full potential of the microbiome to restore health and overcome disease. "Christopher's proven track record in the microbiome field, ranging from product conceptualization to clinical development, will be instrumental in further advancing our R&D strategy and execution," said Laura Figulla, PhD, CEO and Co-founder of mbiomics. “His insights and deep expertise will be a crucial asset enabling us to build an industry-leading pipeline of rationally selected microbial communities unlocking the immunological and metabolic potential of the gut microbiome.” "We as an industry have only scratched the surface of microbiome-based therapy’s potential. mbiomics is aiming to change this by advancing a precise and highly curated approach that combines cutting-edge profiling technologies and patient data insights to address the current bottlenecks in the development of effective, and safe microbiome-based therapeutics. I appreciate the opportunity to join this knowledgeable team and look forward to working together to change the treatment paradigm of severe and chronic diseases," added Christopher Weidenmaier, PhD, CSO of mbiomics. Dr. Weidenmaier previously served as the Director of Research and Head of Host Cell Biology/Immunology at Finch Therapeutics in Somerville, Massachusetts where he led the preclinical discovery and development efforts for microbiome therapeutics before continuing as a Scientific Advisory Board Member. Previously, he worked as Principal Investigator at the University of Tübingen where he authored over 40 scientific publications and received the prestigious research award (Foerderpreis) of the German Society for Microbiology and Hygiene (DGHM). He also held postdoctoral positions at the University of Tübingen and the Division of Infectious Diseases of the Brigham and Women's Hospital and Harvard Medical School in Boston. Dr. Weidenmaier holds a PhD in Microbiology from the University of Tübingen, Germany. About mbiomics mbiomics designs and develops complex microbiome-based therapeutics to change the treatment paradigm of severe and chronic diseases. Bringing together proprietary precision analytics and patient insights, we are building a pipeline of rationally selected microbial communities to achieve indication-specific activity and address patient heterogeneity. Our goal is to access the gut microbiome's full immunological and metabolic potential to restore healthy microbial ecosystems and thereby overcome disease. View source version on businesswire.com: Contacts mbiomics Laura Figulla, PhD, CEO and Co-founder Email: info@mbiomics.com mbiomics media inquiries Trophic Communications Stephanie May, PhD Email: mbiomics@trophic.eu Phone: +49 171 185 56 82 Source: mbiomics View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.